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Purpose. Anti-cancer dendritic cell (DC) vaccines require the DC to relocate to lymph nodes (LN) to trigger immune responses. However, these migration rates are typically very poor. Improving the targeting of ex vivo generated DC to LN might increase vaccine efficacy and reduce costs. We investigated DC migration in vivo in humans in different conditions. Experimental design. HLA-A*02:01 melanoma patients were vaccinated with mature DC loaded with tyrosinase and gp100 peptides together with keyhole limpet hemocyanin (KLH) (NCT00243594). For this study, patients received an additional intradermal (i.d.) vaccination with 111 In-labeled mature DC. The injection site was pretreated with nonloaded, activated DC, TNFα or Imiquimod; GM-CSF was coinjected or smaller numbers of DC were injected. Migration was measured by scintigraphy and compared to an intra-patient control vaccination. In an ex vivo tissue model, we measured CCL21-directed migration of 19 F-labeled DC over a period of up to 12 hours using 19 F MRI to supplement our patient data.
Results. Pretreatment of the injection site induced local inflammatory reactions but
did not improve migration rates. Both in vitro and in vivo, reduction of cell numbers to 5×10 6 or less cells per injection improved migration. Furthermore, scintigraphy is insufficient to study migration of such small numbers of 111 In-labeled DC in vivo.
Conclusion. Reduction of cell density, not pretreatment of the injection site, is crucial for improved migration of DC to LNs in vivo.
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Statement of translational relevance
To trigger an effective immune response, ex vivo generated tumor antigen-loaded DC need to relocate to LN. Intradermal (i.d.) delivery is commonly used, due to its feasibility; however, migration rates never exceeded 4%. Increasing the numbers of ex vivo generated DC reaching LN might therefore increase the vaccine-specific response and reduce costs.
We investigated 111 In-labeled DC migration in vivo in humans after pretreatment of the injection site, using unloaded but activated DC, TNFα or a synthetic TLR7/8
ligand; or co-injection with GM-CSF. Furthermore, we developed an in vitro assay to measure human DC migration in a sensitive and standardized manner.
We show that reduction of cell density, not pretreatment of the injection site, is crucial for improved migration of DC to LN in vivo. However, current imaging modalities for in vivo tracking of DC are insufficient to study migration of small numbers of 111 In-labeled DC in the clinic.
Introduction
Cellular therapy in cancer patients aims to activate the immune system in a highly specific response against the tumor. In most studies, autologous antigen-presenting cells, principally dendritic cells (DC), are activated and loaded with tumor antigen ex vivo (1) . To trigger an effective immune response, the DC need to relocate to immune reactive sites, such as lymph nodes (LN) upon injection back into the patient. Different routes are used to administer the DC to the patients, of which intradermal (i.d.) injection is the most frequently used (2) . The biodistribution of DC after vaccination has been studied in humans, primarily using 111 In or 99m
Tc-labeled DC and scintigraphy (2) . However, even though about 20 clinical trials have been carried out with DC delivered intradermally, the number of cells that reach a LN has never reproducibly exceeded 4% of the total cells injected (2) . Why migration of mature DC from the vaccination site is so poor is still unknown. Several reasons have been suggested, for example the lack of an inflammatory microenvironment which would promote emigration of immune cells to afferent lymphatic vessels. In a mouse model, the migration of bone marrow derived DC into the draining LN could be dramatically increased by pretreating the injection site (3, 4) . The skin was injected with either an extra dose of DC, pro-inflammatory cytokines (TNFα or IL-1α) or Toll-like receptor ligands before injection of the vaccine-DC. This pretreatment of the skin resulted in a five to ten-fold increase in the number of DC in the draining LN that correlated with a similar increase in T cell activation. Other parameters of DC delivery might also contribute to more efficient emigration of DC from the skin to the draining LN, e.g. the frequency of delivery, the infrastructure in terms of vascular and lymphatic networks at site of transplant and the local availability of oxygen and nutrients (5-7).Thus conditioning the injection site, and perhaps indirectly the 6 draining LN, may stimulate the emigration of DC from the skin and directly improve the clinical efficacy of DC-based therapy. Given this multitude of parameters, in vitro cell migration assays are warranted, as they allow high-throughput screening of influences of single parameters or combinations of parameters. The common in vitro cell migration assays that do exist, such as those based on microscopy or platebased migration assays, have some major drawbacks: these techniques typically only work with small numbers of cells or non-opaque samples and thus do not replicate clinical conditions. Furthermore, most techniques assess migration in twodimensional setting, whereas in vivo migration requires motility in 3D. Thus, studying cell migration in vitro in a sensitive and quantitative manner for clinical application is extremely challenging, and not readily feasible with current technology (2) .
In this study, we investigated DC migration in vivo in humans after pretreatment of the injection site, using nonloaded but activated DC, TNFα or Imiquimod (a synthetic TLR7/8 ligand), to induce a local inflammatory microenvironment; or co-injection with GM-CSF to enhance DC survival. We tracked 111
In-labeled vaccine-DC over a period of 48 hours by planar scintigraphy and compared migration to the LN to a standardized control vaccination in the same patient. Furthermore, we modified an in vitro assay that closely reflects in vivo vaccination conditions to measure human DC migration in a standardized manner in tissue samples (8) . By using this model, we measured CCL21 directed migration of 19 F-labeled vaccine-DC over a period of up to 12 hours using 19 F MRI. We show that reduction of cell density, not pretreatment, at the injection site is crucial for improved DC migration in vivo. In particular, we found that cell numbers greater than 1 million reduced migration both in vitro and in vivo.
Furthermore, current clinical imaging modalities for clinical in vivo tracking of DC are insufficient to study migration of small numbers of DC in human studies. (9) . All patients who remained free of disease progression after the first vaccination cycle were eligible for 2 maintenance cycles, each at 6-month intervals and each consisting of 3 biweekly intranodal vaccinations without IL-2.
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Materials and Methods
DC vaccination in melanoma patients
Patients were considered evaluable when they had completed the first vaccination cycle. Vaccine-specific immune response was the primary endpoint, as reported in previous publication (10) .
DC preparation and characterization
KLH-loaded DCs were generated from peripheral blood mononuclear cells (PBMC)
and matured with autologous monocyte-conditioned medium containing prostaglandin E2 (10 mg/mL; Pharmacia & Upjohn) and recombinant TNF-a (10 ng/mL; provided by Dr. G. Adolf, Bender Wien GmbH), as described (29, 30). This procedure gave rise to mature DCs meeting the release criteria (29) and detailed vaccine phenotype is reported in previous publication (10) .
Peptide pulsing
DCs were pulsed with the HLA class I gp100-derived peptides gp100:154-162 and gp100:280-288 and the tyrosinase-derived peptide tyrosinase: 369-377 (31-33).
Peptide pulsing was conducted as described (13), and cells were resuspended in 0.1 mL for injection. For the migration assay, the technique was adapted from (8) to replace the gel scaffold with a tissue sample, in this case bovine muscle. DC were injected as a bolus in the center of a 2 ml Eppendorf tube filled with a single piece of tissue, leaving about 1cm above the tissue as space for medium (see Fig 3a) . The region below the cells formed the control layer to account for nonspecific cell movement or sinking due to gravity, and the region above was the migration region through the use of a chemokine gradient consiting of 0.2μg recombinant human CCL21 (R&D Systems, Minneapolis, MN, USA). 
Histology
Sections (5 μm) of the resected skin from the injection sites were stained with hematoxilin. The staining protocol was done as in (13) . Similar sections were cut from the tissue used for the ex vivo migration assay. These were stained with hematoxilin and an antibody against carbonic anhydrase 9 (CAIX; Novus Biologicals)..
Results
DC migration to LN is poor after intradermal vaccination
In current and previous studies (10, 14) , migration of DC to skin-draining LN after i.d.
injection (n=18) was monitored by labeling the DC vaccine with 111 In and subsequent scintigraphy of injected region (14, 15) . Figure 1A shows the percentage of migrating DC after i.d. injection of 15×10 6 DC at 24 or 48 hrs post-injection. The average migration achieved was 1.2% after 24 hours and 1.4% after 48 hrs, indicating that most of the migration occurred within 24 hrs after injection. Migration rates never exceeded 4% of the total cells injected. Figure 1B shows representative scintigraphs, with the arrow indicating a pretreated site.
The induction of local inflammation of does not improve DC migration
Based on data from mice studies (3, 4), we investigated whether pretreatment of the injection site to create a local inflammatory microenvironment, optimized DC migration. To this end, we pretreated the injection sites with TNFα (n=3), Imiquimod (n=4) or unloaded but activated DC 6 hours (n=3) or 24 hours (n=3) prior to vaccination ( Figures 1A,B) . In patients pretreated with TNFα or activated DC, the contralateral administration of 15×10 6 111 In-labelled vaccine-DC served as intrapatient control. Although the migration from the pretreated site was higher than in the control site in the majority of those patients, it still did not exceeded 4% and did not significantly increase migration compared to unconditioned sites.
Our previous studies have shown that vaccine-DC rapidly lose viability at the injection site after intranodal or intradermal delivery, which might contribute to defective migration to LN (15 
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vaccination might increase the survival of DC and thereby increase migration rates.
Three patients were injected with 15×10 6 DC in normal saline containing 14×10 4 IU GM-SCF. Although the percentage of migrating cells after 48hours was higher than average in 2 of 3 patients, migration was still within the established range. Of note, the induration at the site of injection was markedly larger than after injection of DC alone, suggesting random migration into surrounding dermis.
Lastly, we pretreated the injection site of 4 patients by Imiquimod application every 12 hours for 2 days prior to vaccination. Again, no significant changes in migration rates were documented. Overall, the effects of pretreatment were limited and did not significantly improve subsequent migration of vaccine-DC to the draining LN.
Local cell density is limiting factor
We performed histological analysis of the pretreatment injection sites 48 hours postinjection in order to validate our imaging findings. Injection of DC consistently induced local inflammation, demonstrated by infiltrates of leukocytes around vessels in the dermis, mainly neutrophils and eosinophils. The number of lymphocytes in the dermis increased, compared to normal skin. Pretreatment of the injection site with either TNFα (Figure 2A ,B) or unloaded DC ( Figure 2C) ; or co-injection with GM-CSF ( Figure 2D ) induced some inflammation, as evidenced by the infiltration of leukocytes. However, this did not affect DC emigration.
Histology showed that macrophages had infiltrated the dermis and subcutis around the injection site. In areas with SPIO+ cells were enlarged and exhibited pale pink nuclei, typical for necrotic cells. Thus, the histological evidence shows that DC die at the site of injection and invariably induce an inflammatory response consisting of macrophages and neutrophils. As no apparent differences were noted after different 
pretreatment regimens, together with the notion that dying vaccine-DC were found at higher rates with larger numbers of injected cells; these data suggests that it must be the local cell density itself that hampers efficient emigration of the injection site.
An in vitro assay to study migration of small numbers of DC
To test this hypothesis, we adapted a novel assay we developed to mimic clinical vaccine conditions and which allows reliable quantification of reduced numbers of cells (8) . The assay was modified to use a tissue sample instead of a gel scaffold, as done previously. DCs were cultured as used in patient vaccinations, with the addition of a labeling step for 19 F detection. This labeling has previously been shown to have no effect on the DCs, including their migration (8), ( Figure 3A ). The grid overlay shows the voxels used in the 19 F CSI scans. Imaging was carried out at hourly intervals without moving the sample, and the temperature was regulated. A control area under the cell injection was used to measure passive cell movement due to gravity. CCL21 was used to create a chemokine gradient for active CCR7-mediated migration. The percentage of total cells that migrated was calculated to represent the migratory cells. Figure 3B shows representative cell numbers at 1, 5 and 9 hours after injection of 5 x 10 6 DCs. The migratory and control regions are highlighted.
Reducing the cell density improves migration rates
The following figure ( Figure 4A) shows the migration over time for 5×10 6 DCs, for the migratory region (red) and the control region under the cell layer (blue). These data show that clear migration which is absent in the control region. The overall numbers of cells that migrated were 3×10 4 and 4.5×10 5 with 5×10 5 and 5×10 6 cells, 15 respectively, demonstrating the sensitivity of this assay. Figure 4B summarizes the results of three individual experiments with varying cell numbers in the gel scaffold.
The data indicate that indeed increasing cell number suppresses migration. Thus, the percent of migratory cells is nearly 3% with 0.5 x10 6 and 0% with 15 x10 6 DC.
Finally, histological analyses on the tissue samples, taken over and around the injection site, were analysed ( Figure 4C ). Extensive hypoxia was observed at the injection site (CAIX stain (brown); top panel). Furthermore, at the lower cells numbers, we observed trains of migratory cells (lower panels). These trains appear to be migrating along the muscle tissue, and were completely absent with samples with 15 and 10 x 10 6 million DCs.
Planar scintigraphy not sufficient for imaging of low numbers of injected cells in vivo
Finally, we compared the migration data obtained in vitro using our 19 F MRI assay with the clinical data obtained using scintigraphy on 111 In-labeled DCs (Fig. 5a) We show here that migration rates of human monocyte-derived DC after intradermal injection in melanoma patients could not be increased by pretreatment to induce a pro-inflammatory microenvironment at the injection site. Instead, by using a novel model, we demonstrate in vitro and in vivo that a reduction of cell numbers at the injection site is key to improved migration.
A number of factors might explain the discrepancy between our negative results and the positive effects of pretreatment of the injection site on migration in mice skin.
First, closer analysis of the results in mouse models by Martin-Fontecha et al. to draining LN. In this setting, application of those pro-inflammatory cytokines may act both directly on the DC and indirectly via the surrounding accessory cells. In our study, TNFα is injected to the skin 8 hours prior to DC vaccination and will therefore exert its effect on the microenvironment and not directly on the DC. Given the burden for patients in terms of injections and logistics, we chose not to titrate the dose and timing of TNFα to find the optimum. Moreover, Nair et al demonstrated that by conditioning the skin with the TLR-ligand imiquimod, the migration of immature DC could be stimulated (21) . However, even in this trial no improvement in migration rate was achieved as the injected DC had a mature, and thus highly migratory, phenotype. Finally, note that while several factors contribute to the migration of DC, these can be very difficult to study individually and even more so when considering the costs and logistics of a clinical study. Hence, such factors may best be studied in vitro before final optimization in vivo.
The use of 19 F MRI for quantitative cell tracking is a relatively new technique (12) .
Here we applied this technology to track migratory DC over 10 hours, in order to F labels may also be sensitive to oxygen partial pressures, and thus these can be measured during the experiments to indicate hypoxic regions.
In this paper, we used bovine tissue instead of human tissue to avoid differences due to mismatched immune cells and the inflammatory condition of the tissue.
However, the assay can readily be adapted to use other tissue types. Here we used CCL21 to provide a chemotactic gradient for DC migration. CCL21 is known to induce the active migration of DCs towards lymphatic vessels in vivo (25) .
One of the main issues with 19 F MRI is its sensitivity in terms of detectable cells/voxel/unit imaging time. Under our conditions, we found the sensitivity to be higher than that of clinical scintigraphy ( Figure 5A) ; the sensitivity in our set-up allows the detection of as little as 5000 cells/voxel, compared to 2×10 4 with scintigraphy (16). This is 4-fold higher than the sensitivity of scintigraphy in vivo.
Note that the MRI was carried out on a clinical scanner using sequences that can be applied to humans; using a higher field research magnet and faster imaging sequences would improve sensitivity further. In our experiments, we chose to measure only migration in the vertical plane (i.e. along the chemokine gradient), as The high density of cells at the injection site may prevent the access to sufficient oxygen and nutrients, and may therefore hamper cell movement and active migration. Indeed, hypoxia is evident at the injection site ( Figure 4C ). Hypoxia suppresses the production of matrix metallo-proteinases and the migration of human monocyte derived-DC (3). After injection of a cell suspension in the dermis, the fluid will be readily drained into the afferent lymphatic vessels, due to elasticity of the skin.
The cells however, will be caught in the extracellular matrix and will be packed together, devoid of nutrients and oxygen. The cells on the border of the injection depot may have the opportunity to move away from the depot.
The optimal numbers of DC per LN for adequate immune induction in clinical studies has not been established. Some studies report a dose-dependent relation with immune responses in human (26, 27) . Given the high immune stimulating potential of DC in vitro, it may not be surprising that even small numbers of DC, as in clinical studies, are sufficient. Indeed, we have shown previously that even small numbers of DC are capable of effective interacting with T cells (10, 15) . Hypothetically, the unfavorable conditions at the site of delivery may select the most fit DC with high 21 stimulatory potency, or simply those at the periphery of the bolus, which are then able to migrate to the LN and adequately induce immune responses. Combining this information with the current data, we suggest that multiple intradermal injections with small numbers of cells to target multiple LN basins would increase DC migration to LN, for example using a 'tattoo' delivery device (28). In particular, cells that appear to be actively migratory were only evident with the lower cell numbers ( Figure 4C ). It is possible that DC aggregation or chemotaxis could also be involved in reducing emigration with larger cell numbers, although these factors were not studied here.
In conclusion, we have shown that pretreatment of the skin to create an inflammatory microenvironment at the injection site does not improve DC migration to LN after i.d. Normal skin from patient in Figure 2C , for comparison. 
